HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Web-only Questionnaire Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lewis, D K Articles by Barton, S Search for Related Content PubMed PubMed Citation Articles by Lewis, D K Articles by Barton, S Topic Collections Related Article

Who decides when to start preventive treatment? A questionnaire survey to compare the views of different population subgroups

¹ Vauxhall Primary Health Care, Liverpool, UK
² Editor, Clinical Evidence, BMJ Publishing Group, London, UK

Correspondence to:
Correspondence to:
Dr D Lewis, Vauxhall Primary Health Care, Vauxhall Health Centre, Limekiln Lane, Liverpool L5 8XR, UK;
mariadavid@callaghanlewis.fsnet.co.uk

Accepted for publication 11 September 2002

Keywords: prevention; coronary heart disease; patient preferences

The first 150 words of the full text of this article appear below.

Lipid lowering drugs lower the risk of ischaemic cardiovascular events. The absolute benefit is highest in people at greatest risk of having an event in the near future, but adverse effects and costs are similar whatever the baseline risk. The decision to treat entails balancing expected benefits with expected harms,¹ but is essentially a value judgement. Treatment preferences may vary systematically between groups of people either because they have different levels of baseline risk, or because they have different values and priorities.

Current UK guidelines recommend treatment for those whose 10 year risk of coronary heart disease is at least 30%.^2,3 Assuming a relative risk reduction of one third this is an absolute benefit of about 10% over 10 years (or 5% over five years). Very little is known about the level of coronary risk at which either doctors or patients want treatment.⁴ One small study suggested that patients and . . . [Full text of this article]

Related Article

SOME BY FIRE AND SOME BY THEIR OWN HAND

John R Ashton and Carlos Alvarez-Dardet
J. Epidemiol. Community Health 2003 57: 233. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				T. Marshall Misleading measurements: modeling the effects of blood pressure misclassification in a United States population. Med Decis Making, November 1, 2006; 26(6): 624 - 632. [Abstract] [PDF]

				T Marshall, S Bryan, P Gill, S Greenfield, K Gutridge, and Birmingham Patient Preferences Group Predictors of patients' preferences for treatments to prevent heart disease Heart, November 1, 2006; 92(11): 1651 - 1655. [Abstract] [Full Text] [PDF]

				S Bryan, P Gill, S Greenfield, K Gutridge, T Marshall, and Birmingham Patient Preferences Group Clinicians' preferences for treatments to prevent coronary heart disease: a postal survey Heart, March 1, 2005; 91(3): 377 - 378. [Full Text] [PDF]

				D. K Lewis, J. Robinson, and E. Wilkinson Factors involved in deciding to start preventive treatment: qualitative study of clinicians' and lay people's attitudes BMJ, October 11, 2003; 327(7419): 841. [Abstract] [Full Text] [PDF]